MedTrace Logo

Multicenter Safety Trial Assessing an Innovative Tumor Molecular and Cellular Print Medical Device in Glioma

NCT02077543 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2020-03-25

No results posted yet for this study

Summary

The purpose of the study is to determine the clinical safety and operability of the innovative tissue imprint device ProTool.

Conditions

  • Glioma : Oligodendroglioma or Astrocytoma

Interventions

DEVICE

Brain Tissue Imprint - Medical Device (ProTool)

genomic, transcriptomic and proteomic studies.

Sponsors & Collaborators

  • MEDIMPRINT

    collaborator UNKNOWN

  • Institut National de la Santé Et de la Recherche Médicale, France

    collaborator OTHER_GOV

  • University Hospital, Grenoble

    lead OTHER

Principal Investigators

  • François BERGER, MD, PhD · University Grenoble Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2020-06-30
Completion
2020-12-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02077543 on ClinicalTrials.gov